Core Viewpoint - The company, 泰德医药 (Tide Pharmaceutical), anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, driven by successful strategic implementation and strong demand in the global peptide market [1] Financial Projections - The projected revenue for the fiscal year ending December 31, 2025, is approximately RMB 5.55 billion to RMB 5.85 billion, representing an increase of about 25.5% to 32.3% compared to the estimated revenue of RMB 4.42 billion for the fiscal year ending December 31, 2024 [1] - The expected profit for the fiscal year ending December 31, 2025, is around RMB 2 billion to RMB 2.3 billion, which marks an increase of approximately 237.8% to 288.5% from the estimated profit of RMB 592 million for the fiscal year ending December 31, 2024 [1] - The adjusted net profit (non-IFRS measure) for the fiscal year ending December 31, 2025, is projected to be about RMB 2 billion to RMB 2.3 billion, reflecting an increase of approximately 16.3% to 33.7% compared to the adjusted net profit of RMB 1.72 billion for the fiscal year ending December 31, 2024 [1] Growth Drivers - Revenue growth is primarily attributed to the successful implementation of the "follow-on molecule" strategy, the advantages of the company's integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform, and the strong demand from key clients due to advancements in their R&D pipelines [1] - The rapid expansion of the global peptide market, particularly in the glucagon-like peptide-1 (GLP-1) sector, is also a significant factor contributing to the anticipated growth [1]
泰德医药发盈喜 预期年度经调整净利润约2亿至2.3亿元同比增加约16.3%至33.7%